287 related articles for article (PubMed ID: 30415088)
1. Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials.
Niu HL; Ma YH; Zhang CJ
Int J Surg; 2018 Dec; 60():141-148. PubMed ID: 30415088
[TBL] [Abstract][Full Text] [Related]
2. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
[TBL] [Abstract][Full Text] [Related]
4. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
[TBL] [Abstract][Full Text] [Related]
6. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
Richter HE; Amundsen CL; Erickson SW; Jelovsek JE; Komesu Y; Chermansky C; Harvie HS; Albo M; Myers D; Gregory WT; Wallace D;
J Urol; 2017 Oct; 198(4):890-896. PubMed ID: 28501541
[TBL] [Abstract][Full Text] [Related]
7. Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial.
Abd Wahab HHB; O'Callaghan M
BMC Urol; 2024 Jan; 24(1):16. PubMed ID: 38229041
[TBL] [Abstract][Full Text] [Related]
8. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
[TBL] [Abstract][Full Text] [Related]
9. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
Komesu YM; Amundsen CL; Richter HE; Erickson SW; Ackenbom MF; Andy UU; Sung VW; Albo M; Gregory WT; Paraiso MF; Wallace D;
Am J Obstet Gynecol; 2018 Jan; 218(1):111.e1-111.e9. PubMed ID: 29031894
[TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
Andy UU; Amundsen CL; Honeycutt E; Markland AD; Dunivan G; Dyer KY; Korbly NB; Bradley M; Vasavada S; Mazloomdoost D; Thomas S;
Am J Obstet Gynecol; 2019 Nov; 221(5):513.e1-513.e15. PubMed ID: 31211964
[TBL] [Abstract][Full Text] [Related]
11. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
[TBL] [Abstract][Full Text] [Related]
12. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Yang G; Xu Y; Qu G; Zhang Y
PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
Hendrickson WK; Zhang C; Jelovsek JE; Nygaard IE; Presson AP
J Urol; 2024 Jan; 211(1):134-143. PubMed ID: 37871326
[TBL] [Abstract][Full Text] [Related]
14. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA.
He Q; Li B; Zhang C; Zhang J; Luo D; Wang K
Int Urogynecol J; 2021 Mar; 32(3):477-484. PubMed ID: 32661556
[TBL] [Abstract][Full Text] [Related]
15. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.
Hendrickson WK; Xie G; Rahn DD; Amundsen CL; Hokanson JA; Bradley M; Smith AL; Sung VW; Visco AG; Luo S; Jelovsek JE
Neurourol Urodyn; 2022 Jan; 41(1):432-447. PubMed ID: 34859485
[TBL] [Abstract][Full Text] [Related]
16. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.
Ayeleke RO; Hay-Smith EJ; Omar MI
Cochrane Database Syst Rev; 2013 Nov; (11):CD010551. PubMed ID: 24259154
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
18. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
[TBL] [Abstract][Full Text] [Related]
19. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
Benson K; McCrery R; Taylor C; Padron O; Blok B; de Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman H; Lane F
Neurourol Urodyn; 2020 Jun; 39(5):1482-1488. PubMed ID: 32339339
[TBL] [Abstract][Full Text] [Related]
20. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
